Tab Title Description
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:1. Patients diagnosed with drug resistant epilepsy (DRE)2. Patients who have received or will receive EVO® sEEG-RF implants3. Patients who have undergone or may undergo an RF ablation procedure using the OneRF Ablation System.4. Patient, or legal guardian, understands study procedures and voluntarily signs informed consent in accordance with institutional policies. In the event that the patient is under the age of 18, the patient may also be required (per IRB) to sign an assent affirming their agreement to participate.Exclusion Criteria:1. Any condition that, in the judgement of the clinician, would make the participant inappropriate for registry participation
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 06/15/2026. Questions regarding updates should be directed to the study team contact.
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Brin Freund, M.D.
Contact us for the latest status
Brin Freund
9049536869
Contact Usfreund.brin@mayo.edu